Apr 20, 2012 | Contract Pharma Breaking News
SkyePharma Earns Pacira Milestone
SkyePharma has received a milestone payment of $10 million from Pacira Pharmaceuticals, following the launch of Exparel in the U.S. Exparel's NDA was approved by the FDA on October 31, 2011.
SkyePharma, RespiVert Ink Second Feasibility Pact
SkyePharma has signed a second agreement to conduct a feasibility study with RespiVert Ltd.
Shares in SkyePharma rose despite the drug development firm reporting a fall in revenue and a plunge into the red for the year ended December 31st.